Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations and Comprehensive Loss

v3.25.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Research and development $ 13,005,986 $ 5,600,193
General and administrative 3,155,735 3,231,042
Total operating expenses 16,161,721 8,831,235
Loss from operations (16,161,721) (8,831,235)
Other income 171,282 0
Interest income 404,020 429,039
Net loss (15,586,419) (8,402,196)
Other comprehensive income (loss):    
Foreign currency translation gain (loss) 1,630 (17,272)
Unrealized gain (loss) on investments 48,494 (5,802)
Comprehensive loss $ (15,536,295) $ (8,425,270)
Net loss per share:    
Basic and diluted (in dollars per share) $ (4.11) $ (3.04)
Weighted average shares outstanding:    
Basic and diluted** (in shares) [1] 3,790,202 2,764,790
[1] Information pertaining to number of shares outstanding and per share data gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024.